These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 15977441

  • 1. Efficacy and safety of enoxaparin, a low molecular weight heparin in the prevention of deep vein thrombosis in Nigerian patients after orthopaedic surgery.
    Akanmu AS, Nnodu OE, Giwa SO, Salako LA, Akinsete I, Adebule GT, Adekoya-Cole TO, Odunubi OO.
    Afr J Med Med Sci; 2004 Dec; 33(4):335-40. PubMed ID: 15977441
    [Abstract] [Full Text] [Related]

  • 2. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
    Turpie AG, Eriksson BI, Lassen MR, Bauer KA.
    J South Orthop Assoc; 2002 Dec; 11(4):182-8. PubMed ID: 12597061
    [Abstract] [Full Text] [Related]

  • 3. The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination.
    Perhoniemi V, Vuorinen J, Myllynen P, Kivioja A, Lindevall K.
    Ann Chir Gynaecol; 1996 Dec; 85(4):359-63. PubMed ID: 9014067
    [Abstract] [Full Text] [Related]

  • 4. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R, Hülsmann M, Spitzauer S, Pabinger I, Heinz G.
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [Abstract] [Full Text] [Related]

  • 5. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, Sinha U, Gretler DD, EXPERT Study Group.
    Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
    [Abstract] [Full Text] [Related]

  • 6. Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin.
    Peled E, Rovitsky A, Axelman E, Norman D, Brenner B, Nadir Y.
    Thromb Res; 2012 Jul; 130(1):129-34. PubMed ID: 22154361
    [Abstract] [Full Text] [Related]

  • 7. Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery.
    Planes A.
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S33-5; discussion S37-8. PubMed ID: 8180327
    [Abstract] [Full Text] [Related]

  • 8. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H, Videm V, Wahba A, Asberg A, Amundsen T, Bjella L, Dale O, Stenseth R.
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [Abstract] [Full Text] [Related]

  • 9. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
    Tetri S, Hakala J, Juvela S, Saloheimo P, Pyhtinen J, Rusanen H, Savolainen ER, Hillbom M.
    Thromb Res; 2008 Jun; 123(2):206-12. PubMed ID: 18420258
    [Abstract] [Full Text] [Related]

  • 10. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL, Chen J, Qiao SB, Guo YL, Wu YJ, Dai J, Yuan JQ, Qin XW, Yang YJ, Gao RL.
    Chin Med J (Engl); 2006 Mar 05; 119(5):355-9. PubMed ID: 16542576
    [Abstract] [Full Text] [Related]

  • 11. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P, ODIXa-HIP Study Investigators.
    Circulation; 2006 Nov 28; 114(22):2374-81. PubMed ID: 17116766
    [Abstract] [Full Text] [Related]

  • 12. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P.
    Thromb Res; 2007 Nov 28; 120(5):685-93. PubMed ID: 17292948
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
    Monreal L, Villatoro AJ, Monreal M, Espada Y, Anglés AM, Ruiz-Gopegui R.
    Am J Vet Res; 1995 Oct 28; 56(10):1281-5. PubMed ID: 8928943
    [Abstract] [Full Text] [Related]

  • 14. Thrombocytosis after prophylactic administration of enoxaparin: unexpected findings in a Polish prospective multicenter trial on the efficacy and safety of enoxaparin in the prevention of postoperative thromboembolism.
    Ziaja K, Simka M, Krupowies A, Dugaj M, Ludyga T.
    Int Angiol; 1999 Mar 28; 18(1):65-9. PubMed ID: 10392483
    [Abstract] [Full Text] [Related]

  • 15. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M.
    Clin Ther; 2009 Jul 28; 31(7):1559-67. PubMed ID: 19695405
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels.
    Saw J, Kereiakes DJ, Mahaffey KW, Applegate RJ, Braden GA, Brent BN, Brodie BR, Groce JB, Levine GN, Leya F, Moliterno DJ.
    Thromb Res; 2003 Jul 28; 112(5-6):301-6. PubMed ID: 15041274
    [Abstract] [Full Text] [Related]

  • 17. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S, Breyer HG, Bacher HP, Fareed J, Misselwitz F, Victor N, Weber J, ECHOS Trial Group.
    Int Angiol; 2006 Dec 28; 25(4):335-42. PubMed ID: 17164738
    [Abstract] [Full Text] [Related]

  • 18. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C, Omran H, Tripp C, Poetzsch B.
    Thromb Haemost; 2009 Feb 28; 101(2):325-32. PubMed ID: 19190817
    [Abstract] [Full Text] [Related]

  • 19. Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy.
    Narin C, Reyhanoglu H, Tülek B, Onoglu R, Ege E, Sarigül A, Yeniterzi M, Durmaz I.
    Adv Ther; 2008 Jun 28; 25(6):585-94. PubMed ID: 18568442
    [Abstract] [Full Text] [Related]

  • 20. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
    Vincent PD, Albert M, Champagne MC, Zikos T, Boulanger I, Blais L, Williamson DR.
    J Crit Care; 2011 Aug 28; 26(4):347-51. PubMed ID: 21454037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.